Elucidating the role of a cross-cell-type microRNA-125a network in sepsis-induced coagulopathy

Sepsis is a life-threatening condition in which a dysregulated immune response can lead to organ failure. One frequent and particularly dangerous complication is sepsis-induced coagulopathy. In this condition, the coagulation system becomes imbalanced, and small blood clots can form. As a result, blood flow to vital organs may be further impaired. The mechanisms underlying this coagulation disorder are still incompletely understood.

GluN2D antagonist as a rapid-acting antidepressant

Depression is one of the most prevalent and disabling disorders worldwide. Current antidepressants often take weeks to work and fail in a significant number of patients. The project aims to develop a novel, fast-acting, and well-tolerated antidepressant by targeting the GluN2D subunit of the NMDA receptor - a mechanism the scientists identified as key to ketamine’s antidepressant effects in preclinical studies.

Network-Informed Single-Session Interventions for youth waiting for psychotherapy – a personalized approach for rapid access to mental health treatment (NISSI for Youth)

In Germany, young people with mental health problems often wait up to six months for treatment. These delays can worsen symptoms, lead to chronic problems, or cause school difficulties. Quick help, like single-session interventions (SSI), can bridge this gap and prevent deterioration. This study tests whether two personalized SSIs, tailored to each individual’s needs, work better than standard SSIs. Personalized SSIs will focus on the symptom that is most linked to others in individual symptom networks, based on either a self-reported perceived causal or a data-driven network model.

Immune cells to combat cancer, autoimmune disorders, and infectious diseases: Else Kröner-Fresenius-Stiftung calls for nominations for the 2027 Prize for Medical Research

Bad Homburg v. d. Höhe, June 18, 2026 – The Else Kröner-Fresenius-Stiftung (EKFS) is now accepting nominations for the 2027 Else Kröner Fresenius Prize for Medical Research. Endowed with €2.5 million, the prize will be awarded in Bad Homburg on June 3, 2027, and will recognize outstanding achievements in the field of cell-based immunotherapies.

Else Kröner Fresenius Prize for Medical Research 2027

In honor of the outstanding lifetime achievements of Else Kröner, the founder of the Else Kröner-Fresenius-Stiftung, the foundation has established this major biennial research prize to be awarded in a specified field of biomedical science. The field chosen for 2027 is “Cell-based immunotherapies”.

The prize amounts to EUR 2.5 million, of which EUR 500,000 shall be awarded personally to the recipient and EUR 2.0 million dedicated to the award-winner’s future research.

HEAL: To investigate the effects of endurance exercise training on systemic 3-hydroxyanthranilic acid (3-HAA) levels and other biological markers of aging in middle-aged adults - a randomized controlled trial

The aging process is associated with an increased risk of chronic diseases and a decline in physical and cognitive functions. Physical activity, particularly endurance exercise training, can counteract these changes, but the underlying biological mechanisms are largely unclear. The "HEAL" project investigates whether endurance exercise training mediates anti-aging effects via the metabolism of the amino acid tryptophan in middle-aged adults.